Tesamorelin vs Ipamorelin: GHRH Receptor vs Ghrelin Receptor

Tesamorelin and ipamorelin both increase growth hormone (GH) secretion, but through different receptors. Tesamorelin is a modified full-length GHRH that activates the GHRH receptor. Ipamorelin is a small synthetic peptide that activates the ghrelin receptor (GHSR). They differ about seven-fold in size and have very different evidence bases. Researchers often pair them, and “tesamorelin + ipamorelin” blends are sold for that reason.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Tesamorelin: GHRH receptor agonist; 44 residues; ~5136 g/mol.
Ipamorelin: ghrelin receptor agonist; 5 residues; 711.9 g/mol.
Tesamorelin has phase 3 data and a licensed indication; ipamorelin has early human PK/PD data.
Ipamorelin is selective: in swine it did not raise ACTH or cortisol.
The pathways converge on pituitary GH release, the rationale for studying them together.

Side-by-side comparison

	Tesamorelin	Ipamorelin
Receptor	GHRH receptor	GHSR-1a (ghrelin receptor)
Structure	trans-3-hexenoyl-GHRH(1-44)-NH₂	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Mass	~5136 g/mol	711.9 g/mol
Natural counterpart	GHRH (hypothalamic hormone)	Ghrelin (gut hormone), acting at the same receptor
Human PK	Once-daily in phase 3 trials	Terminal half-life ~2 h
Hormone selectivity	GH-specific via GHRH-R	GH without ACTH/cortisol rise in swine
Clinical evidence	Phase 3; licensed for a specific indication	Phase 1 PK/PD

Both are available for research: tesamorelin and ipamorelin.

Two receptors, one output

The GHRH receptor signals mainly through cAMP in somatotrophs and drives GH synthesis and release (Halmos et al., 2025). GHSR is a separate GPCR with constitutive activity, increased by ghrelin and reduced by the endogenous antagonist LEAP2. Besides GH release, it is involved in food intake and glucose homeostasis (Cornejo et al., 2021). In the original ipamorelin pharmacology, antagonist experiments confirmed that ipamorelin acts through a GHRP-type receptor and not the GHRH receptor (Raun et al., 1998). Because the two receptors use different signalling routes, combining a GHRH-R agonist with a GHSR agonist is a standard experimental approach to probing GH regulation.

Evidence base compared

Evidence	Tesamorelin	Ipamorelin
Animal pharmacology	GHRH analogue literature	Rat and swine potency/selectivity (Raun et al., 1998)
Human pharmacokinetics	Clinical program	Dose-proportional; t_1/2 ~2 h; GH peak ~0.67 h (Gobburu et al., 1999)
Phase 3 trials	Two 26-week trials in HIV-associated abdominal fat (Falutz et al., 2007; Dhillon, 2011)	None identified

In the first phase 3 trial, visceral adipose tissue fell 15.2% with tesamorelin versus a 5.0% rise with placebo, and IGF-I rose 81% (Falutz et al., 2007). Ipamorelin’s human data describe a single GH episode after each infusion, consistent with its short half-life (Gobburu et al., 1999).

About “tesamorelin + ipamorelin” blends

Blends of the two are marketed for research convenience. Things to check:

Ratio: confirm the weight of each component. Because ipamorelin is about 7.2 times lighter than tesamorelin, equal weights give roughly seven ipamorelin molecules per tesamorelin molecule.
Identity: the components differ by over 4 kDa, so MS and HPLC resolve them easily; the COA should report both.
Evidence: we are not aware of peer-reviewed studies of this specific combination.

Designing a comparison experiment

Because the two act through different receptors, a clean comparison includes receptor-specific controls. A GHRH-receptor antagonist should block tesamorelin’s effect but not ipamorelin’s, and a GHSR antagonist should do the opposite. This is the approach Raun and colleagues used to show that ipamorelin acts through a GHRP-type receptor. Measuring GH over time matters too. Ipamorelin produces a single short GH episode, so sampling schedules designed for a once-daily GHRH analogue may miss its peak.

Handling

Both: lyophilized powder at −20 °C; solutions at 2–8 °C, dark; avoid freeze–thaw.
Tesamorelin contains Met27 (oxidation, +16 Da); ipamorelin has no Met or Cys.
Both dissolve in water; tesamorelin may need longer gentle swirling.
Concentrations: peptide reconstitution calculator; method: how to reconstitute peptides.

Open questions

Does combining these two specific peptides produce additive or synergistic GH responses, and does it alter pulsatility?
How does GHSR constitutive activity influence the response to ipamorelin when GHRH-R is also being stimulated?

Related research

Frequently asked questions

What is the difference between tesamorelin and ipamorelin?

They stimulate growth hormone through different receptors. Tesamorelin is a 44-residue GHRH analogue acting on the GHRH receptor; ipamorelin is a 5-residue peptide acting on the growth hormone secretagogue (ghrelin) receptor.

Can tesamorelin and ipamorelin be used together in research?

Researchers study GHRH-receptor and ghrelin-receptor agonists together because the two pathways converge on GH release. A ‘tesamorelin + ipamorelin blend’ combines one of each; we are not aware of peer-reviewed studies of that specific combination.

Which has more clinical evidence?

Tesamorelin, which has phase 3 trials and a licensed indication. Ipamorelin’s human data are mainly early pharmacokinetic and pharmacodynamic studies.

How do their half-lives compare?

Ipamorelin’s terminal half-life in healthy men was about 2 hours. Tesamorelin is protected from DPP-4 cleavage by its N-terminal modification and was given once daily in phase 3 trials.

Is tesamorelin a ghrelin agonist?

No. Tesamorelin acts only on the GHRH receptor; ipamorelin is the ghrelin-receptor agonist of the pair.

References

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822 https://pubmed.ncbi.nlm.nih.gov/9849822/
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658 https://pubmed.ncbi.nlm.nih.gov/10496658/
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PMID: 18057338 https://pubmed.ncbi.nlm.nih.gov/18057338/
Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID: 21668043 https://pubmed.ncbi.nlm.nih.gov/21668043/
Cornejo MP, et al. The ups and downs of growth hormone secretagogue receptor signaling. FEBS J. 2021. PMID: 33460513 https://pubmed.ncbi.nlm.nih.gov/33460513/
Halmos G, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. PMID: 39934495 https://pubmed.ncbi.nlm.nih.gov/39934495/